Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 12th Annual Meet on Bacteriology & Applied Microbiology Singapore.

Day 1 :

OMICS International Bacteriology Asia Pacific 2018 International Conference Keynote Speaker Dr Donald Kuah  photo
Biography:

Donald Kuah is an experienced Sports and Exercise Physician specialist and one of the founding practitioners at Sydney Sports Medicine Centre in Olympic Park. He has been the Chief Medical Officer to the Wests Tigers NRL team (2003-2013), is the current Chairman of the NRL Medical Advisory Panel and is on the Olympic Winter Institute of Australia medical panel. He was the NSW Institute of Sport Medical Director from 2000-2012, being responsible for the state’s top 700 elite athletes and remains involved with treating NSWIS athletes. Dr Kuah is involved in teaching at many levels and also heavily involved in clinical research. He
has previously been the State Training Coordinator for the Australasian College of Sport and Exercise Medicine and continues to be a Clinical Training Supervisorand an Examiner for the College. His interest areas lie in treatment of tendon pathologies, osteoarthritis, hamstring origin pathologies and also in the area of
regenerative medicine.

Abstract:

Osteoarthritis (OA) is a debilitating condition with no known cure or disease-modifying treatments available. Stem cell therapies may have the potential to halt OA disease progression and repair and regenerate affected joints. Bone Marrow (BM) and adipose-derived (AD) MSCs are being trialed for multiple diseases including OA but the majority of research has involved use of autologous cells (rather than allogeneic). A brief review of the literature will be presented. Two studies of knee OA patients receiving allogeneic BM-MSCs concluded MSCs were safe but varying efficacy results were reported. One study reported significant decreases in pain and encouraging MRI results in the MSC treated group. The second study observed no significant changes in objective and subjective pain measurements and no cartilage improvements by MRI. Allogeneic MSC safety has also been demonstrated in a cartilage defect study and in a study delivering the MSCs post partial meniscectomy. These studies reported improvements in pain and MRI measurements in patients that received MSCs. The STEP (Safety, tolerability and Efficacy of Progenza) Trial was a first-in-human, Phase I, randomised, double-blind, placebo-controlled single
ascending dose study of Progenza (PRG) for OA. PRG is composed of in vitro expanded AD-MSCs derived from human donor
adipose tissue combined with cell culture supernatant, frozen in ready to inject vials. The primary objective was to evaluate the
safety and tolerability of PRG administered via a single intra-articular injection. Secondary objectives included investigating the
effect of PRG on pain, function and joint structures in the study knee, quality of life and relevant serum and urine biomarkers.
Twenty patients (40-65 years; Kellgren-Lawrence grade 1-3 knee OA and 35-90mm visual analogue scale pain score) were
treated in two cohorts of 10 patients with a 12 month follow-up. Cohort 1: 3.9 million cells (n=8) or placebo (n=2) and cohort
2: 6.7 million cells (n=8) or placebo (n=2). All patients experienced at least 1 treatment emergent adverse event. Most were
mild and unrelated to the Investigational Product (IP). No serious adverse events were reported, and no patients withdrew
from the study due to an AE. VAS pain scores (Fig. 1) and WOMAC pain subscale scores significantly improved from baseline
at all timepoints in the PRG groups (p < 0.05) whilst only a marginal non-statistically significant improvement was observed
in the placebo group. Lateral tibial cartilage volume was preserved in the PRG 3.9M group whilst the placebo group showed a
statistically significant cartilage loss. PRG was safe and well tolerated when administered as a single intra-articular injection to
patients with symptomatic knee OA. Improvements in knee structure outcomes demonstrates the potential for PRG to have a
disease modifying effect in OA joints which warrants further investigation.

OMICS International Bacteriology Asia Pacific 2018 International Conference Keynote Speaker Christoper John N Tibayan photo
Biography:

Christoper John N Tibayan is a Diplomat in Internal Medicine and is a Member of the Philippine College of Physicians. He has completed his Doctorate in Medicine from Far Eastern University.

Abstract:

Sepsis-3 Guidelines promoted the new definition and prognostication scheme among patients with sepsis using the Sequential Organ Failure Assessment (SOFA) Scoring System. The study determined the discriminative power of the 2nd day SOFA scoring system in predicting 30-day hospital mortality among adult Filipino patients who presented with sepsis and suggested adjustment on the applicability of SOFA scoring system in a resource limited government hospital in the Philippines. We evaluated 107 adults with sepsis presenting at the emergency department from June to August 2017 at Ospital Ng
Makati, Philippines. Receiving operating characteristic curves were generated to determine optimal cut off scores of SOFA in
predicting 30-day mortality. Binary logistic regression was performed to determine the association of the SOFA derivatives with
hospital mortality.

OMICS International Bacteriology Asia Pacific 2018 International Conference Keynote Speaker Gomathi Swaminathan photo
Biography:

Mrs. Gomathi Swaminathan, M.Pharm., is perusing part-time Ph.D in The Tamil Nadu Dr. M.G.R Medical University, Chennai, Tamilnadu, India and is a full-time faculty of J. K. K. Nattraja College of Pharmacy, Kumarapalayam, Tamilnadu, India. Her field of doctoral and research work is primarily on herbal phytoconstituents and medicines for neurodegenerative disorders. She has published 20 research articles in various national and international journals and has received many best poster and oral presentation awards, young scientist award in various national and international conferences.     

Abstract:

Neurodegenerative diseases (ND) are threatening worldwide. Huge number of behavioural changes are associated with ND such as depression, anxiety, memory loss, stress and so on. Effective drugs need to cure the ND from nature. In this present study, we had evaluated the phytochemical analysis and neuroprotective activity of Pedalium murex Linn (PM) leaves against bacterial cell wall content Lipopolysaccharide (LPS)-induced endotoxemia in rats. Two compounds were isolated from 90% v/v of ethanol extract of Pedalium murex Linn (EEPM) named as PM I, PM II. Spectral data of isolated compounds strongly suggested that PM I showed the structural similarities with 4´, 5, 7- trihydroxy flavone may be Apigenin and PM II showed the structural similarities with 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one which may have the presence of kaempferol. The data of our present study revealed that LPS significantly decreases the food, water intake and body mass which was recovered EEPM treated rats.  EEPM attenuated or completely abolished the symptoms of depression and anxiety. Antioxidant enzymes includes SOD, CAT, GR, GPX levels were decreased in LPS-treated rats, which was recovered by EEPM treated rats. Histopathological results also support the neuroprotective effect of EEPM against LPS-induced neurodegeneration. We  may conclude that EEPM may be a potential candidate for LPS-induced brain damage which may be attributed to the presence of potent antioxidants in EEPM